Hepatic encephalopathy (HE) is a common complication in patients with advanced liver
disease. It is a brain dysfunction characterized by neurological and psychiatric symptoms …

1 ESGE recommends that patients with compensated advanced chronic liver disease
(ACLD; due to viruses, alcohol, and/or nonobese [BMI< 30 kg/m 2] nonalcoholic …

Sarcopenia in patients with liver cirrhosis (LC) has been attracting much attention these
days because of the close linkage to adverse outcomes. LC can be related to secondary …

The present systematic review with meta-analysis was undertaken to review the evidence
base in support of a beneficial effect of L-ornithine L-aspartate (LOLA) for the …

Effective lowering of circulating ammonia is the mainstay strategy in the prevention and
treatment of hepatic encephalopathy in cirrhosis and there is increasing interest in agents …

Impairments in liver function lead to different complications. As chronic liver disease
progresses (CLD), hypoalbuminemia and alterations in bile acid compositions lead to …

Objective: Rifaximin has been approved for use as a first-line therapy for secondary
prophylaxis of hepatic encephalopathy (HE). This article is to update existing evidence on …

Hepatic encephalopathy (HE) is a common complication of advanced liver disease and
acute liver failure. It is a condition that features several neuropsychiatric symptoms that affect …

La primera guía clínica sobre la encefalopatía hepática se publicó en el año 2009, a casi 14
años de esta primera publicación, numerosos avances en el campo del diagnóstico …

The first clinical guidelines on hepatic encephalopathy were published in 2009. Almost 14
years since that first publication, numerous advances in the field of diagnosis, treatment, and …